Clinical Trial Update: OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OPTIMOX-aflibercept as first-line therapy for unresectable metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Unresectable Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED